Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin-Reference-Cited by-同舟云学术

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

Published:2010-06-08 Issue:11 Volume:89 Page:1133-1140
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Buda Gabriele,Ricci Deborah,Huang C. Chris,Favis Reyna,Cohen Nadine,Zhuang Sen H.,Harousseau Jean-Luc,Sonneveld Pieter,Bladé Joan,Orlowski Robert Z.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://www.springerlink.com/index/pdf/10.1007/s00277-010-0992-3

Reference38 articles.

1. Kumar SK, Therneau TM, Gertz MA et al (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 79:867–874

2. Shah JJ, Orlowski RZ (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23:1964–1979

3. Dimopoulos MA, Kastritis E, Rajkumar SV (2008) Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 22:1343–1353

4. Laubach JP, Mahindra A, Mitsiades CS et al (2009) The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 23:2222–2232

5. Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123–2132

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Correlation Between the Membrane Assembly of P-gp and Drug Resistance in Multiple Myeloma Using Super-Resolution Fluorescence Imaging;Analytical Chemistry;2024-07-12

2. Pharmacogenomics of Cancer Chemotherapy: Transporter Polymorphisms and Drug Response;Interdisciplinary Cancer Research;2024

3. Expression and DNA methylation of 20S proteasome subunits as prognostic and resistance markers in cancer;2023-12-12

4. DNA Topoisomerase Targeting Drugs;Holland‐Frei Cancer Medicine;2022-10-21

5. Drug Targeting and Conventional Treatment of Multiple Myeloma: Analysis of Target-specific Nanotherapies in Disease Models;Current Drug Therapy;2022-10